ONTX logo

Onconova Therapeutics (ONTX) Stock

Profile

Full Name:

Traws Pharma, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

25 July 2013

Indexes:

Not included

Description:

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

May 15, 2024

Recent annual earnings:

Mar 16, 2023
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

May 21, 2021

Analyst ratings

Recent major analysts updates

12 Oct '23 HC Wainwright & Co.
Buy
11 Aug '23 HC Wainwright & Co.
Buy
14 June '23 HC Wainwright & Co.
Buy
06 June '23 HC Wainwright & Co.
Buy
25 May '23 HC Wainwright & Co.
Buy
16 May '23 HC Wainwright & Co.
Buy
21 Apr '23 HC Wainwright & Co.
Buy
01 Mar '22 Ladenburg Thalmann
Buy
18 May '21 Guggenheim
Buy
22 Dec '20 Noble Capital Markets
Outperform

Screeners with ONTX included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Similar stocks

Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript
Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript
Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript
ONTX
Seeking Alpha14 November 2023

Onconova Therapeutics, Inc. (NASDAQ:ONTX ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Steve Fruchtman - President and CEO Victor Moyo - Chief Medical Officer Mark Guerin - Chief Operating Officer and CFO Meena Arora - VP of Global Medical Affairs & Research and Development, Conference Call Participants Edouard Mullarky - Guggenheim Partners Ahu Demir - Ladenburg Thalmann Robert LeBoyer - Noble Capital Markets James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Welcome to Onconova Therapeutics Third Quarter 2023 Financial Results and Business Update Conference Call.

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
ONTX
GlobeNewsWire07 November 2023

NEWTOWN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its third quarter 2023 financial results on Tuesday, November 14, 2023.

Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript
Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript
Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript
ONTX
Seeking Alpha10 August 2023

Onconova Therapeutics, Inc. (NASDAQ:ONTX ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Dr. Steve Fruchtman - President and CEO Dr. Victor Moyo - Consultant Chief Medical Officer Mark Guerin - Chief Operating Officer and CFO Fred Frullo - Vice President, Regulatory Affairs and Quality Assurance Conference Call Participants Edouard Mullarky - Guggenheim Ahu Demir - Ladenburg Thalmann Robert LeBoyer - Noble Capital Markets Operator Ladies and gentlemen, thank you for standing by. Welcome to the Onconova Therapeutics Second Quarter [Technical Difficulty] Dr. Steve Fruchtman Sarah, excuse me, you are coming in and out and I don't know if other people hear.

Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript
Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript
Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript
ONTX
Seeking Alpha15 May 2023

Onconova Therapeutics, Inc. (NASDAQ:ONTX ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Bruce Mackle - Managing Director, LifeSci Advisors Steven Fruchtman - President and Chief Executive Officer Michael Saunders - Interim Chief Medical Officer Mark Guerin - Chief Operating Officer and Chief Financial Officer Conference Call Participants Joseph Pantginis - H.C. Wainwright Ahu Demir - Ladenburg Thalmann Robert LeBoyer - Noble Life Science Partners Operator Ladies and gentlemen, thank you for standing by.

Onconova Therapeutics, Inc. (ONTX) Reports Q1 Loss, Misses Revenue Estimates
Onconova Therapeutics, Inc. (ONTX) Reports Q1 Loss, Misses Revenue Estimates
Onconova Therapeutics, Inc. (ONTX) Reports Q1 Loss, Misses Revenue Estimates
ONTX
Zacks Investment Research15 May 2023

Onconova Therapeutics, Inc. (ONTX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.20 per share a year ago.

FAQ

  • What is the primary business of Onconova Therapeutics?
  • What is the ticker symbol for Onconova Therapeutics?
  • Does Onconova Therapeutics pay dividends?
  • What sector is Onconova Therapeutics in?
  • What industry is Onconova Therapeutics in?
  • What country is Onconova Therapeutics based in?
  • When did Onconova Therapeutics go public?
  • Is Onconova Therapeutics in the S&P 500?
  • Is Onconova Therapeutics in the NASDAQ 100?
  • Is Onconova Therapeutics in the Dow Jones?
  • When was Onconova Therapeutics's last earnings report?
  • When does Onconova Therapeutics report earnings?
  • Should I buy Onconova Therapeutics stock now?

What is the primary business of Onconova Therapeutics?

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

What is the ticker symbol for Onconova Therapeutics?

The ticker symbol for Onconova Therapeutics is NASDAQ:ONTX

Does Onconova Therapeutics pay dividends?

No, Onconova Therapeutics does not pay dividends

What sector is Onconova Therapeutics in?

Onconova Therapeutics is in the Healthcare sector

What industry is Onconova Therapeutics in?

Onconova Therapeutics is in the Biotechnology industry

What country is Onconova Therapeutics based in?

Onconova Therapeutics is headquartered in United States

When did Onconova Therapeutics go public?

Onconova Therapeutics's initial public offering (IPO) was on 25 July 2013

Is Onconova Therapeutics in the S&P 500?

No, Onconova Therapeutics is not included in the S&P 500 index

Is Onconova Therapeutics in the NASDAQ 100?

No, Onconova Therapeutics is not included in the NASDAQ 100 index

Is Onconova Therapeutics in the Dow Jones?

No, Onconova Therapeutics is not included in the Dow Jones index

When was Onconova Therapeutics's last earnings report?

Onconova Therapeutics's most recent earnings report was on 15 May 2024

When does Onconova Therapeutics report earnings?

The date for Onconova Therapeutics's next earnings report has not been announced yet

Should I buy Onconova Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions